Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lanreotide Acetate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Ipsen
Deal Size : Undisclosed
Deal Type : Financing
Details : Ipsen’s extensive experience with Somatuline Autogel / Somatuline Depot has offered deep insights into the challenges of living with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome or acromegaly.
Product Name : Somatuline Autogel
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
March 16, 2022
Lead Product(s) : Lanreotide Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Ipsen
Deal Size : Undisclosed
Deal Type : Financing
Reset All
